Catheter Precision, Inc. Announces Two New Patents to be Issued by USPTO
Catheter Precision (NYSE:VTAK), a medical device company specializing in cardiac electrophysiology, has received approval for two new patents from the United States Patent and Trademark Office (USPTO).
The first patent, "Methods of Ventricular Arrhythmia Localization Using a 3D Model," will be assigned to Kardionav, a joint venture between Catheter Precision and physicians. The second patent, "Neurostimulation Devices and Methods," focused on improving cardiac ventricular function in heart failure patients, will be assigned to Cardionomix, a majority-owned subsidiary of Catheter Precision.
Catheter Precision (NYSE:VTAK), un'azienda di dispositivi medici specializzata in elettrofisiologia cardiaca, ha ottenuto l'approvazione per due nuovi brevetti dall'Ufficio americano dei brevetti e dei marchi (USPTO).
Il primo brevetto, "Metodi per la Localizzazione di Fibrillazione Ventricolare mediante un modello 3D", sarà assegnato a Kardionav, una joint venture tra Catheter Precision e i medici. Il secondo brevetto, "Dispositivi e Metodi di Neurostimolazione", focalizzato sul miglioramento della funzione ventricolare cardiaca nei pazienti con insufficienza cardiaca, sarà assegnato a Cardionomix, una controllata per la maggioranza di Catheter Precision.
Catheter Precision (NYSE:VTAK), una empresa de dispositivos médicos especializada en electrofisiología cardíaca, ha recibido la aprobación para dos nuevas patentes por la Oficina de Patentes y Marcas de EE. UU. (USPTO).
La primera patente, "Métodos de Localización de Arritmias Ventriculares utilizando un modelo 3D", se asignará a Kardionav, una empresa conjunta entre Catheter Precision y médicos. La segunda patente, "Dispositivos y Métodos de Neuroestimulación", centrada en mejorar la función ventricular cardíaca en pacientes con insuficiencia cardíaca, se asignará a Cardionomix, una subsidiaria mayoritaria de Catheter Precision.
Catheter Precision (NYSE:VTAK), 심장 전기생리학을 전문으로 하는 의료기기 회사가 미국 특허청(USPTO)으로부터 두 가지 신규 특허 승인을 받았습니다.
첫 번째 특허인 "3D 모델을 이용한 심실 부정맥 위치화 방법"은 Kardionav에 할당될 예정이며, 이는 Catheter Precision과 의사들 간의 합작 투자 company입니다. 두 번째 특허인 "신경자극 디바이스 및 방법"은 심부전 환자의 심실 기능 향상에 초점을 맞추고 있으며 Cardionomix, Catheter Precision의 다수 지분 자회사에 할당될 예정입니다.
Catheter Precision (NYSE:VTAK), entreprise de dispositifs médicaux spécialisée en électrophysiologie cardiaque, a obtenu l'approbation pour deux nouveaux brevets par l'Office américain des brevets et des marques (USPTO).
Le premier brevet, intitulé "Méthodes de localisation des arythmies ventriculaires à l'aide d'un modèle 3D", sera attribué à Kardionav, une coentreprise entre Catheter Precision et des médecins. Le second brevet, "Dispositifs et méthodes de neurostimulation", axé sur l'amélioration de la fonction ventriculaire chez les patients atteints d’insuffisance cardiaque, sera attribué à Cardionomix, une filiale majoritaire de Catheter Precision.
Catheter Precision (NYSE:VTAK), ein auf kardiovaskuläre Elektrophysiologie spezialisiertes Medizingeräteteam, hat die Zulassung für zwei neue Patente vom United States Patent and Trademark Office (USPTO) erhalten.
Das erste Patent, "Methoden zur Lokalisierung ventrikulärer Arrhythmien mittels eines 3D-Modells", wird an Kardionav vergeben, ein Joint Venture zwischen Catheter Precision und Ärzten. Das zweite Patent, "Neurostimulationsgeräte und -methoden", das darauf abzielt, die ventrikuläre Funktion bei Herzinsuffizienzpatienten zu verbessern, wird an Cardionomix, eine Mehrheits-Tochtergesellschaft von Catheter Precision, vergeben.
Catheter Precision (NYSE:VTAK)، شركة أجهزة طبية especializada في الفيزيولوجيا الكهربائية القلبية، قد حصلت على موافقة لـ براءتين جديدتين من مكتب براءات الاختراع والعلامات التجارية الأمريكية (USPTO).
البراءة الأولى، "طرق تحديد موضع اضطراب النظم البطيني باستخدام نموذج ثلاثي الأبعاد"، ستُمنح إلى Kardionav، وهي مشروع مشترك بين Catheter Precision وأطباء. البراءة الثانية، "أجهزة وطرق التحفيز العصبي"، التي تركّز على تحسين وظيفة البطين القلبي لدى مرضى فشل القلب، ستُمنح إلى Cardionomix، وهي شركة فرعية مملوكة في الأغلبية لـCatheter Precision.
Catheter Precision (NYSE:VTAK)，专注于心脏电生理学的医疗器械公司，已获得美国专利商标局（USPTO）批准的 两项新专利。
第一项专利“使用三维模型进行室性心律失常定位的方法”将分配给 Kardionav，这是 Catheter Precision 与医生之间的合资企业。第二项专利“神经刺激装置与方法”，旨在改善心衰患者的心室功能，将分配给 Cardionomix，Catheter Precision 的控股子公司。
- Strengthening of intellectual property portfolio with two new USPTO patents
- Strategic expansion in cardiac therapy through joint venture Kardionav
- Development of unique products for competitive medical device market through Cardionomix subsidiary
- None.
FORT MILL, S.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced that it has received notification from the United States Patent and Trademark Office of the allowance for issuance of two new patents.
One patent is entitled “Methods of Ventricular Arrhythmia Localization Using a 3D Model”. This patent is another milestone of adding to the VIVO technology intellectual property portfolio, and will be assigned to Kardionav, the joint venture between Catheter Precision and physicians to bring in new applications to cardiac ventricular therapies.
The second patent is entitled, “Neurostimulation Devices and Methods”, which is oriented toward improvement of cardiac ventricular function, especially in patients with heart failure. This patent will be assigned to Cardionomix, a majority owned subsidiary of Catheter Precision. Cardionomix holds a number of patents, with the intent to pursue heart failure therapy, primarily through stimulation of certain nerve endings found in the pulmonary arteries.
David Jenkins, CEO of Catheter Precision, commented, “We are pleased that additional intellectual property is being confirmed through the issuance of patents by the USPTO. This creates value for our different areas of technology and solidifies our beliefs that our products can be unique in a competitive medical device marketplace. We continue to have several applications on file and will continue to pursue new applications as a matter of our ongoing strategy.”
About VIVO™
Catheter Precision’s VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
FAQ
What new patents did Catheter Precision (VTAK) receive from the USPTO?
How will the new VTAK patents impact their business?
Which subsidiaries will own Catheter Precision's new patents?
What is Catheter Precision's (VTAK) focus in medical technology?
